Want to see ESLOY full AI Analyst Report?
ESLOY Stock Chart & Stats
$159.07
-$0.84(-0.69%)
At close: 4:00 PM EST
$159.07
-$0.84(-0.69%)
Day’s Range― - ―
52-Week Range$93.38 - $186.18
Previous CloseN/A
Volume9.05K
Average Volume (3M)2.59K
Market Cap
$87.67B
Enterprise Value$162.05K
Total Cash (Recent Filing)$3.54B
Total Debt (Recent Filing)$14.40B
Price to Earnings (P/E)33.4
Beta0.85
Next Earnings
Jul 28, 2026EPS Estimate
2.22Next Dividend Ex-DateN/A
Dividend Yield1.41%
Share Statistics
EPS (TTM)2.52
Shares Outstanding928,495,100
10 Day Avg. Volume2,986
30 Day Avg. Volume2,591
Financial Highlights & Ratios
PEG Ratio-8.26
Price to Book (P/B)3.18
Price to Sales (P/S)4.34
P/FCF Ratio34.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.11
Revenue Forecast (FY)$34.87B
Bulls Say, Bears Say
Bulls Say
Vertical Integration & Brand PortfolioControl of design, manufacturing, wholesale and owned retail creates durable margin capture and speed-to-market. Vertical integration supports pricing, product mix control and recurring sales from prescription replacement cycles, anchoring long-term revenue resilience and competitive moat.
Sustained Revenue Growth And Record Free Cash FlowMulti-year revenue expansion plus record free cash flow provide durable funding for R&D, retail rollout and M&A without relying solely on external capital. Strong cash generation underpins reinvestment in wearables and med‑tech and supports shareholder returns over the medium term.
Scale In Wearables & Med‑tech With Regulatory WinsRapid consumer adoption of AI glasses and FDA‑authorized myopia solutions create new, higher‑growth addressable markets. Regulatory edge and product scale drive stickier clinical partnerships and cross‑sell into prescriptions, supporting sustained structural revenue and differentiation.
Bears Say
Gross Margin CompressionSignificant margin erosion from tariffs and a rapid shift to lower‑margin wearables reduces operating leverage. Even if scale later improves unit economics, persistent tariff or FX pressures and mix shifts can structurally cap operating margin expansion in the medium term.
Rising LeverageAn upward debt trajectory reduces financial flexibility and raises interest expense sensitivity in a higher‑rate environment. Higher leverage limits strategic optionality for M&A or buybacks and increases downside risk if cash generation weakens or investment needs rise.
Moderate Cash Conversion And FCF VolatilityWhile absolute FCF is large, sub‑optimal cash conversion and year‑to‑year volatility reduce predictability of internal funding. Working‑capital timing and episodic FCF swings can constrain consistent reinvestment, dividend stability or deleveraging plans during cyclical slowdowns.
EssilorLuxottica SA News
ESLOY FAQ
What was EssilorLuxottica SA’s price range in the past 12 months?
EssilorLuxottica SA lowest stock price was $93.38 and its highest was $186.18 in the past 12 months.
What is EssilorLuxottica SA’s market cap?
EssilorLuxottica SA’s market cap is $87.67B.
When is EssilorLuxottica SA’s upcoming earnings report date?
EssilorLuxottica SA’s upcoming earnings report date is Jul 28, 2026 which is in 12 days.
How were EssilorLuxottica SA’s earnings last quarter?
EssilorLuxottica SA released its earnings results on Feb 11, 2026. The company reported $1.729 earnings per share for the quarter, beating the consensus estimate of $1.573 by $0.156.
Is EssilorLuxottica SA overvalued?
According to Wall Street analysts EssilorLuxottica SA’s price is currently Overvalued.
Does EssilorLuxottica SA pay dividends?
EssilorLuxottica SA pays a Annually dividend of $2.317 which represents an annual dividend yield of 1.41%. See more information on EssilorLuxottica SA dividends here
What is EssilorLuxottica SA’s EPS estimate?
EssilorLuxottica SA’s EPS estimate is 2.22.
How many shares outstanding does EssilorLuxottica SA have?
EssilorLuxottica SA has 928,495,100 shares outstanding.
What happened to EssilorLuxottica SA’s price movement after its last earnings report?
EssilorLuxottica SA reported an EPS of $1.729 in its last earnings report, beating expectations of $1.573. Following the earnings report the stock price went down -0.343%.
Which hedge fund is a major shareholder of EssilorLuxottica SA?
Currently, no hedge funds are holding shares in ESLOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EssilorLuxottica SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 50.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.83%
12-Months-Change
Fundamentals
Return on Equity
6.04%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
EssilorLuxottica SA
EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. The company specializes in the creation, production, and worldwide distribution of a diverse range of vision products, including ophthalmic lenses, eyewear frames, and sunglasses, catering to markets across North America, Europe, Latin America, Asia, Oceania, and Africa. Its extensive operations are divided into five key segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division is responsible for manufacturing and supplying premium and athletic eyewear to other businesses. Conversely, the Retail segment directly offers luxury and sports eyewear to consumers through its various sales channels. The Lenses and Optical Instruments segment provides a broad spectrum of lenses, such as Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (including the Gen 8 series), Eyezen lenses optimized for digital screen use, and Xperio polarized sun lenses, alongside corrective options from Nikon and Kodak. This segment also furnishes optical instruments, including lens edging and mounting equipment for opticians and laboratories, and optometry tools for a variety of professionals and institutions, while also developing online optical sales solutions. The Equipment segment focuses on delivering advanced digital surfacing and lens coating machinery to prescription laboratories, integrated optical chains, and lens manufacturers. Lastly, the Sunglasses and Readers segment encompasses a wide array of non-prescription sunglasses and reading glasses, available under numerous well-known proprietary brands like Foster Grant, Magnivision, and SolarShield, licensed brands such as Reebok, Steve Madden, and Disney, and regional labels including Bolon and Mujosh. To support its expansive business, EssilorLuxottica maintains a substantial network of 490 prescription laboratories and edging-mounting facilities globally. The company formally adopted the name EssilorLuxottica Société anonyme in October 2018, having previously been known as Essilor International Société Anonyme.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors












